Zydus Lifesciences Ltd. announced today that the group’s injectables manufacturing facility at Zydus Biotech Park in Changodar, Ahmedabad, was inspected by the USFDA.
USFDA conducted the inspection between June 5 to June 13, 2023. The company said that the cGMP inspection resulted in no observations.
The Zydus Group is a worldwide life sciences company focused on enabling individuals to live healthier and more satisfying lives. With a core objective of empowering people, the company engages in innovative practices to discover, develop, manufacture, and market a diverse portfolio of healthcare therapies.
Following this development, Zydus Lifesciences was trading 0.75% higher at Rs 521.55, against the previous close of Rs 517.65 on NSE. The counter touched an intraday high and low of Rs 523.90 and Rs 515.60 respectively.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
